A biotech had successfully completed Phase I clinical trials and was rapidly progressing into Phase II. Serious adverse event (SAE) volume was expected to significantly increase and therefore associated workload could not be managed in-house.
Qinecsa established a compliant and robust drug safety framework in line with budget and quality expectations to manage increased case volumes.
Join Qinecsa at 32nd Pharmacovigilance 2023, 26-27 April, Boston
Join Qinecsa at 32nd Pharmacovigilance 2023 to discuss the latest developments in pharmacovigilance, drug safety & risk management.Our President, Humaira Qureshi, will present ‘Fit for future sourcing for pharmacovigilance’ where she will discuss the drivers for...
